Michael R Megna Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

Michael R Megna is CHIEF ACCOUNTING OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 27,443 shares of KNSA, which is worth approximately $633,658. The most recent transaction as insider was on Mar 16, 2025, when has been sold 328 shares (Class A Ordinary Share) at a price of $22.61 per share, resulting in proceeds of $7,416. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 27.4K

3.45% 3M change

43.97% 12M change

Total Value Held $633,658

Michael R Megna Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 16 2025	SELL Payment of exercise price or tax liability	$7,416 $22.61 p/Share	328 Reduced 1.18%	27,443 Class A Ordinary Share
Mar 16 2025	BUY Exercise of conversion of derivative security	-	774 Added 2.71%	27,771 Class A Ordinary Share
Mar 12 2025	SELL Open market or private sale	$203,194 $22.45 p/Share	9,051 Reduced 25.44%	26,528 Class A Ordinary Share
Mar 12 2025	BUY Exercise of conversion of derivative security	$100,466 $11.1 p/Share	9,051 Added 20.28%	35,579 Class A Ordinary Share
Jan 15 2025	BUY Grant, award, or other acquisition	$7,504 $16.0 p/Share	469 Added 1.71%	26,997 Class A Ordinary Share
Nov 29 2024	SELL Open market or private sale	$202 $22.45 p/Share	9 Reduced 0.03%	26,528 Class A Ordinary Share
Nov 29 2024	BUY Exercise of conversion of derivative security	$99 $11.1 p/Share	9 Added 0.03%	26,537 Class A Ordinary Share
Nov 27 2024	SELL Open market or private sale	$193,900 $22.45 p/Share	8,637 Reduced 24.56%	26,528 Class A Ordinary Share
Nov 27 2024	BUY Exercise of conversion of derivative security	$95,870 $11.1 p/Share	8,637 Added 19.72%	35,165 Class A Ordinary Share
Oct 04 2024	SELL Payment of exercise price or tax liability	$2,007 $24.48 p/Share	82 Reduced 0.31%	26,528 Class A Ordinary Share
Oct 04 2024	BUY Exercise of conversion of derivative security	-	175 Added 0.65%	26,610 Class A Ordinary Share
Sep 02 2024	SELL Payment of exercise price or tax liability	$8,797 $26.74 p/Share	329 Reduced 1.23%	26,435 Class A Ordinary Share
Sep 02 2024	BUY Exercise of conversion of derivative security	-	775 Added 2.81%	26,764 Class A Ordinary Share
Sep 01 2024	SELL Payment of exercise price or tax liability	$73,668 $26.74 p/Share	2,755 Reduced 9.58%	25,989 Class A Ordinary Share
Sep 01 2024	BUY Exercise of conversion of derivative security	-	6,490 Added 18.42%	28,744 Class A Ordinary Share
Jul 15 2024	BUY Grant, award, or other acquisition	$7,512 $15.65 p/Share	480 Added 2.11%	22,254 Class A Ordinary Share
Apr 08 2024	SELL Payment of exercise price or tax liability	$29,821 $17.9 p/Share	1,666 Reduced 7.25%	21,328 Class A Common Share
Apr 08 2024	BUY Exercise of conversion of derivative security	-	3,932 Added 14.6%	22,994 Class A Common Share
Apr 01 2024	SELL Payment of exercise price or tax liability	$21,354 $19.7 p/Share	1,084 Reduced 5.38%	19,062 Class A Common Share
Apr 01 2024	BUY Exercise of conversion of derivative security	-	2,558 Added 11.27%	20,146 Class A Common Share
Mar 01 2024	SELL Open market or private sale	$207,185 $21.45 p/Share	9,659 Reduced 35.45%	17,588 Class A Common Share
Mar 01 2024	BUY Exercise of conversion of derivative security	$109,726 $11.36 p/Share	9,659 Added 26.17%	27,247 Class A Common Share
Feb 28 2024	SELL Open market or private sale	$111,695 $21.79 p/Share	5,126 Reduced 22.57%	17,588 Class A Common Share
Feb 28 2024	BUY Exercise of conversion of derivative security	$45,262 $8.83 p/Share	5,126 Added 18.41%	22,714 Class A Common Share
Jan 15 2024	BUY Grant, award, or other acquisition	$7,200 $12.35 p/Share	583 Added 3.21%	17,588 Class A Common Share

MRM

Michael R Megna

CHIEF ACCOUNTING OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account